Full-Time
Mental Health Therapist
Telehealth
Updated on 8/22/2026
Affect Therapeutics
51-200 employees
Digital addiction treatment with contingency management
Compensation Overview
$60k - $80k/yr
Remote in USA
Remote
Must be licensed in New Mexico; remote work requires a private HIPAA-compliant workspace and reliable internet.
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Affect Therapeutics
See people who can refer or advise you
- Maintain an active and verifiable New Mexico license as an LCSW, LPCC, LMFT, LISW, or LMHC, along with a license in the state of residence if it is not New Mexico; credentials must be verified through the State Board’s website.
- Have experience providing psychotherapy in outpatient, private practice, or telehealth settings.
- Demonstrate strong communication and clinical skills with a person-centered, trauma-informed approach.
- Be comfortable with electronic medical records, Google Suite or Microsoft Office, and telehealth tools.
- Work independently in a remote setting with professionalism and integrity.
- Have a private, HIPAA-compliant workspace and reliable internet.
- Conduct diagnostic assessments and collaboratively develop evidence-based treatment plans.
- Provide individual psychotherapy sessions via secure telehealth platforms.
- Support members with mental health needs including anxiety, depression, trauma, relationship challenges, and, when needed, substance use disorders.
- Maintain clear and timely clinical documentation in the electronic medical record system.
- Coordinate care as needed and contribute to a supportive, multidisciplinary environment.
- Participate in clinical team meetings and optional case consultations.
- Adhere to HIPAA and all applicable state licensure regulations.
- Ability or interest in working with non-independent mental health licenses where state and license regulations permit supervision.
- Flexibility to work with members with substance use disorders.
Affect Therapeutics provides digital addiction recovery services that combine contingency management with therapy and medication. The platform is private, fully online, and accessible via secure video conferencing, removing the need to visit clinics. It uses financial incentives to reward healthy behaviors, helping users build new habits, and offers holistic support such as job search, housing guidance, and bill management to improve overall life circumstances. The business likely operates on a subscription or fee-for-service model to fund ongoing treatment and support. Compared to traditional clinics, the service emphasizes digital convenience, privacy, and integrated life-support, aiming to help people recover from addiction and improve their broader daily life.
Company Size
51-200
Company Stage
Series B
Total Funding
$49M
Headquarters
New York City, New York
Founded
2020
Get referred to Affect Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Affect closed a $26 million Series B on September 23, 2025.
- Hiring remains active in July 2026, signaling expansion rather than contraction.
- Partnership messaging targets health plans, employers, and state agencies for faster distribution.
What critics are saying
- Behavioral-health reimbursement shifts could crush margins if payers tighten contingency-management coverage in 2026.
- Virtual addiction treatment faces relentless competition from Hazelden, Bicycle Health, and Brightside-style platforms.
- If clinical outcomes lag, the $26 million Series B becomes a short runway to retrenchment.
What makes Affect Therapeutics unique
- Contingency management plus therapy and medication anchors Affect's addiction treatment model.
- Affect serves Medicaid, Medicare, and employer plans across 20 states.
- Its fully digital clinic pairs an app with counselors, PMHNPs, and case managers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Remote Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -3%2 year growth
↓ -1%Affect Therapeutics, a digital mental health and addiction treatment provider, has raised $26M in a Series B funding round led by Allumia Ventures. The company offers therapy, medical support, and a gamified app for conditions like depression, PTSD, anxiety, OCD, and substance use disorders. It operates in several U.S. states and accepts major insurance plans. Previously, Affect Therapeutics raised $23M, including a $16M Series A in 2023.
Affect Therapeutics, a provider of all-digital addiction treatment programs, raised $16 million in a Series A round led by Artis Ventures.
Affect Therapeutics, a McLean, VA-based company providing addiction treatment for the digital age, raised $16M in Series A funding.The round was led by ARTIS Ventures with additional participation from previous investors AlleyCorp and CityLight, as well as new investments from LifeArc Ventures, Samsung Next, and What If Ventures. Stuart Peterson of ARTIS Ventures has joined the Board, and Dr. Imran Hamid of LifeArc Ventures joined the Board as an observer. The company intends to use the funds to enable national expansion, program expansion, and engineering innovation in the Affect app.Founded in 2020, Affect Therapeutics offers clinically intensive treatment that follows a scientifically-proven program supporting the entire recovery journey via a smartphone app for drug and alcohol addiction. The approach, based on the best research in the field including its own NIH-sponsored studies, combines experts at unlocking behavior change and motivation, with members receiving rewards for success in treatment, including engagement and provision of negative drug and alcohol screens. The company’s approach couples this type of cognitive behavioral therapy with counseling, medical oversight, and case management, delivering a comprehensive program based on decades of research.Affect currently holds outpatient treatment licenses in 20 states and aims to serve a majority of the U.S. population by the end of 2023
Affect Therapeutics (“Affect”), a company reimagining addiction treatment for the digital age, today announces a $16 million Series A led by TechBio-focused ARTIS Ventures with additional participation from previous investors AlleyCorp and CityLight, as well as new investments from LifeArc Ventures, Samsung Next, and What If Ventures.
There are any number of seed rounds that cross our desks every day, a never-ending march of enterprise software, consumer apps, games, hardware, biotech, and sometimes even a space startup. But amid the regular flow of funding news, it’s still rare to come across a company raising money to take on addiction with software. So when Affect’s $1 million seed round from AlleyCorp came to my attention, I wanted to learn a bit more.